Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and Professor Karl Wagner from the University of Bonn, announce the results of new research confirming Jungbunzlauer’s tricalcium citrate (TCC TB) sets a new standard for direct compression in pharmaceutical and nutraceutical tablet manufacturing.
“This collaboration with Professor Wagner and his workgroup from the Department of Pharmaceutical Technology and Biopharmaceutics at the University of Bonn underscores our commitment to rigorous science, innovation and product excellence,” said Markus Gerhart, senior director of Category Lead Minerals & Solutions at Jungbunzlauer. “Through validated research, we’re proud to demonstrate that our TCC TB delivers reliable performance in direct compression, helping our customers achieve efficiency, quality, and confidence.”
Direct compression is increasingly favoured for its efficiency and suitability for sensitive ingredients, but it demands excipients with exceptional flow and compactibility. The study results confirm Jungbunzlauer’s TCC TB delivers excellent flowability, robust tablet strength at low compression force, and rapid disintegration, even for challenging formulations such as minitablets, moisture-sensitive APIs, and botanical actives.
Produced by complete neutralisation of citric acid with a high-purity calcium source, TCC TB is certified vegan, allergen and GMO-free, and meets USP, FCC, and EU standards.
The new findings will be presented at CPHI Global, Messe Frankfurt (Hall 8, Booth Q55) from 28–30 October 2025. Attendees are invited to discuss the data with Jungbunzlauer and explore how TCC TB can naturally support your next formulation challenge.